Antibiotics in treatment of peritonsillar infection: clindamycin versus penicillin

J Laryngol Otol. 2021 Jan;135(1):64-69. doi: 10.1017/S002221512100013X. Epub 2021 Jan 22.

Abstract

Objective: This study aimed to compare antibiotic treatment with clindamycin versus penicillin V or G in terms of time to recovery and recurrence in patients with peritonsillar infection, including both peritonsillar cellulitis and peritonsillar abscess.

Method: This retrospective cohort study examined the records of 296 patients diagnosed with peritonsillar infection. Based on the ENT doctor's choice of antibiotics, patients were divided into clindamycin and penicillin groups.

Results: Mean number of days in follow up was 3.5 days in the clindamycin group and 3.4 days in the penicillin group. The recurrence rate within 2 months was 7 per cent in the clindamycin group and 4 per cent in the penicillin group.

Conclusion: This study found no significant differences in either recovery or recurrence between the groups. This supports the use of penicillin as a first-line treatment, considering the greater frequency of adverse effects of clindamycin shown in previous studies, as well as its profound collateral damage on the intestinal microbiota, resulting in antibiotic resistance.

Keywords: Anti-Bacterial Agents; Clindamycin; Penicillins; Peritonsillar Abscess.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • Cellulitis / drug therapy*
  • Child
  • Clindamycin / therapeutic use*
  • Cohort Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Penicillins / therapeutic use*
  • Peritonsillar Abscess / drug therapy*
  • Recurrence
  • Retrospective Studies
  • Tonsillitis / drug therapy*
  • Treatment Outcome
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Penicillins
  • Clindamycin